Table 1 Patient’s clinical characteristics. Data is expressed as the mean ± SEM of values from healthy control donors (CT) and osteoarthritis patients (OA) according to the gender (female (F), male (M)) and for all subjects
From: Heparan sulfate functions are altered in the osteoarthritic cartilage
Patients | CT | OA | ||||
|---|---|---|---|---|---|---|
Sex | F | M | All | F | M | All |
 Number | 6 | 1 | 7 | 5 | 6 | 11 |
 Age (year) | 82 ± 5 | 88 | 83 ± 4 | 78 ± 9 | 74 ± 6 | 75 ± 7 |
 Lenght (cm) | 160 ± 1 | 178 | 166 ± 8 | 156 ± 2 | 178 ± 3 | 169 ± 10 |
 Weight (kg) | 56 ± 6 | 95 | 64 ± 12 | 66 ± 2 | 97 ± 16 | 84 ± 19 |
OA severity | ||||||
 (K-L global) | 1.7 ± 0.4 | 1 | 1.6 ± 0.5 | 4 ± 0 | 4 ± 0 | 4 ± 0 |
 Menopause | Yes | NC |  | Yes | NC |  |
 Analgesics | NC | NC | NC | 0 | 3 | 3 |
 AINS | NC | NC | NC | 0 | 1 | 1 |
 Corticoid | NC | NC | NC | 1 | 0 | 1 |
 Hyaluronic Acid | NC | NC | NC | 1 | 0 | 1 |
 Period of symptoms (Year) | NC | NC | NC | 12.5 ± 2.5 | 9 ± 3 | 10 ± 2 |